Zevra TherapeuticsZVRA
About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Employees: 59
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
133% more call options, than puts
Call options by funds: $3.74M | Put options by funds: $1.61M
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
16% more capital invested
Capital invested by funds: $271M [Q1] → $314M (+$43M) [Q2]
6% more funds holding
Funds holding: 109 [Q1] → 115 (+6) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
0.25% less ownership
Funds ownership: 65.5% [Q1] → 65.25% (-0.25%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities Jason N. Butler | 92%upside $18 | Market Outperform Maintained | 13 Aug 2025 |
Cantor Fitzgerald Kristen Kluska | 210%upside $29 | Overweight Maintained | 10 Jul 2025 |
HC Wainwright & Co. Brandon Folkes | 178%upside $26 | Buy Initiated | 2 Jul 2025 |
Financial journalist opinion
Based on 11 articles about ZVRA published over the past 30 days
